Works matching DE "ATEZOLIZUMAB"

Results: 381
    1
    2
    3
    4
    5

    Commentary.

    Published in:
    Oncology in Clinical Practice (2450-1654), 2023, v. 19, n. 6, p. 444, doi. 10.5603/OCP.2023.0002
    By:
    • Krzakowski, Maciej
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21

    Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 6, p. 510, doi. 10.1159/000533166
    By:
    • Vogel, Arndt;
    • Finn, Richard S.;
    • Blanchet Zumofen, Marie-Hélène;
    • Heuser, Carolina;
    • Sanchez Alvarez, Javier;
    • Leibfried, Michael;
    • Mitchell, Catherine R.;
    • Batson, Sarah;
    • Redhead, Gabrielle;
    • Gaillard, Vincent E.;
    • Kudo, Masatoshi
    Publication type:
    Article
    22

    Erratum.

    Published in:
    2023
    Publication type:
    Correction Notice
    23

    Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 4, p. 321, doi. 10.1159/000529574
    By:
    • Kudo, Masatoshi;
    • Aoki, Tomoko;
    • Ueshima, Kazuomi;
    • Tsuchiya, Kaoru;
    • Morita, Masahiro;
    • Chishina, Hirokazu;
    • Takita, Masahiro;
    • Hagiwara, Satoru;
    • Minami, Yasunori;
    • Ida, Hiroshi;
    • Nishida, Naoshi;
    • Ogawa, Chikara;
    • Tomonari, Tetsu;
    • Nakamura, Noriaki;
    • Kuroda, Hidekatsu;
    • Takebe, Atsushi;
    • Takeyama, Yoshifumi;
    • Hidaka, Masaaki;
    • Eguchi, Susumu;
    • Chan, Stephen L
    Publication type:
    Article
    24

    IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 238, doi. 10.1159/000528272
    By:
    • Kudo, Masatoshi;
    • Finn, Richard S.;
    • Galle, Peter R.;
    • Zhu, Andrew X.;
    • Ducreux, Michel;
    • Cheng, Ann-Lii;
    • Ikeda, Masafumi;
    • Tsuchiya, Kaoru;
    • Aoki, Ken-ichi;
    • Jia, Jing;
    • Lencioni, Riccardo
    Publication type:
    Article
    25

    Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 251, doi. 10.1159/000528145
    By:
    • Ando, Yuwa;
    • Kawaoka, Tomokazu;
    • Kosaka, Masanari;
    • Shirane, Yuki;
    • Johira, Yusuke;
    • Miura, Ryoichi;
    • Murakami, Serami;
    • Yano, Shigeki;
    • Amioka, Kei;
    • Naruto, Kensuke;
    • Kosaka, Yumi;
    • Uchikawa, Shinsuke;
    • Kodama, Kenichiro;
    • Fujino, Hatsue;
    • Nakahara, Takashi;
    • Ono, Atushi;
    • Murakami, Eisuke;
    • Yamauchi, Masami;
    • Okamoto, Wataru;
    • Takahashi, Shoichi
    Publication type:
    Article
    26

    Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    27

    Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000527759
    By:
    • Hosoda, Shunichi;
    • Suda, Goki;
    • Sho, Takuya;
    • Ogawa, Koji;
    • Kimura, Megumi;
    • Yang, Zijian;
    • Yoshida, Sonoe;
    • Kubo, Akinori;
    • Tokuchi, Yoshimasa;
    • Kitagataya, Takashi;
    • Maehara, Osamu;
    • Ohnishi, Shunsuke;
    • Nakamura, Akihisa;
    • Yamada, Ren;
    • Ohara, Masatsugu;
    • Kawagishi, Naoki;
    • Natsuizaka, Mitsuteru;
    • Nakai, Masato;
    • Morikawa, Kenichi;
    • Furuya, Ken
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    Subcutaneous Atezolizumab: A Jab Without a Benefit.

    Published in:
    Clinical Pharmacology in Drug Development, 2022, v. 11, n. 1, p. 134, doi. 10.1002/cpdd.1061
    By:
    • Peer, Cody J.;
    • Zimmerman, Sara M.;
    • Figg, William D.;
    • Goldstein, Daniel A.;
    • Ratain, Mark J.
    Publication type:
    Article
    39

    Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer.

    Published in:
    Clinical Pharmacology in Drug Development, 2021, v. 10, n. 10, p. 1142, doi. 10.1002/cpdd.936
    By:
    • Felip, Enriqueta;
    • Burotto, Mauricio;
    • Zvirbule, Zanete;
    • Herraez‐Baranda, Luis A.;
    • Chanu, Pascal;
    • Kshirsagar, Smita;
    • Maiya, Vidya;
    • Chan, Phyllis;
    • Pozzi, Emanuela;
    • Marchand, Mathilde;
    • Monchalin, Marion;
    • Tanaka, Kunihiko;
    • Tosti, Nadia;
    • Wang, Bei;
    • Restuccia, Eleonora
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50